期刊文献+

卡马西平固体脂质纳米粒处方与制备工艺优化 被引量:1

Optimization of Formulation and Preparation Procedure of Cambamazepine SLN
下载PDF
导出
摘要 目的优选卡马西平固体脂质纳米粒(SLN)的处方及制备工艺。方法采用正交实验法对卡马西平-单硬脂酸甘油酯用量比(A)、泊洛沙姆用量(B)、吐温80用量(C)、超声时间(D)等4个因素选取3个水平,考察卡马西平固体脂质纳米粒包封率,用直观法和方差分析法分析结果。结果影响因素为:卡马西平-单硬脂酸甘油酯用量比>吐温80用量>泊洛沙姆用量>超声时间。结论卡马西平SLN最佳制备工艺为:A3B1C1D1,即卡马西平-单硬脂酸甘油酯质量比为10:100,泊洛沙姆用量为100 mg,超声时间为5 min,不用吐温80。 Objective To determine the optimum formulation and preparation procedure of cambamazepine SLN, Methods Three levels in each of four factors ( the ratio of earhamazepine and glycerol monostearate, quantity of poloxamer and tween-80, time of ultrasonic processing) were selected with orthogonal design. The encapsulation efficiency of cambamazepine SLN was tested. The results were analyzed by means of direct-viewing and ANOVA . Results The important four factors were ranked as follow : the ratio of carbamazepine and glycerol monostearate 〉 quantity of tween-80 〉 quantity of poloxamer 〉 time of the ultrasonic processing. Conclusion The optimum formulation and preparation procedure of cambamazepine SLN were that : using 10 : 100 of carbamazepine and glycerol monostearate, consuming 100 mg poloxamer and 0 mg tween-80, and taking 5 min of ultrasonic processing.
出处 《医药导报》 CAS 2009年第9期1192-1194,共3页 Herald of Medicine
基金 陕西省科技攻关项目[基金编号:2004K10-G4(3)]
关键词 卡马西平 纳米粒 制备工艺 正交实验 Cambamazepine SLN Preparation procedure Orthogonal design methods
  • 相关文献

参考文献5

二级参考文献41

  • 1胡惠民,黄乾明.小檗碱提取新工艺[J].中国中药杂志,1993,18(7):419-420. 被引量:14
  • 2[1]Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism[J]. Eur J Pharm Biopharrn, 1998, 45(3): 149. 被引量:1
  • 3[2]Kopecek I, Kopeckoya P, Minko T. HPMA copolymer bound anticancer drug mechanism of action on cellular and subcellular levels [J]. Prog Int Symp Cont rolled Rel Bioact Mater, 1999,26 ( 1 ): 24. 被引量:1
  • 4[3]Torchilin VP. Liposomes as targetable drug carriers[J]. Crit Rev Ther Drug Carrier Syst, 1985,2(2): 65. 被引量:1
  • 5[4]Trotta M, Pattarino F, Ignoni T. Stability of drug-carrier emul sions containing phosphatidylcholine mixtures[J]. Eur J Pharm Biopharm, 2002,53(4): 203. 被引量:1
  • 6[5]MμLler RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles( SLN)-an alternative colloidal carrier system for controlleddrug delivery[J ]. Eur J Pharm Biopharm, 1995,41 (2): 62. 被引量:1
  • 7[6]Jahmke S. The theory of high pressure homogenization[ M]. in:Muller RH, Benita S, Emulsion and nanosuspensions for the for mulation of poorly soluble drugs. Medpharm Scientific Publish ers, stuttgart, B Bohm(Eds), 1998.177. 被引量:1
  • 8[7]Antonio JA, Runge S, Muller RH. Peptide-loaded solid lipid nanoparticles(SLN): influence of production parameters[J]. Int J Pharm, 1997, 149(6):255. 被引量:1
  • 9[8]Siekmann B, Westesen K. Investigation on solid lipid nanoparti cles prepared by precipitation in O/W emulsion[J]. Eur J Pharm Biopharm, 1996,43(2): 104. 被引量:1
  • 10[9]Gasco MS. Method for producing solid lipid nanospheres having a narrow size distribution[ P]. US Patent, 5250236, 1993-11-01. 被引量:1

共引文献72

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部